- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Hepatitis C Drugs on WHO's "Essential Medicines" List
The addition by the World Health Organization follows requests by consumer groups for the agency to widen its list to include some of the latest treatments carrying high price tags.
As the debate over the cost of prescription drugs accelerates, the World Health Organization has added several treatments for cancer and hepatitis C to its list of so-called essential medicines, which the agency believes should be made available at affordable prices.
The move comes amid growing friction between payers — both public and private – and the pharmaceutical industry over drug pricing. The addition by the WHO follows requests by consumer groups for the agency to widen its list to include some of the latest treatments carrying high price tags.
Among the drugs added to the list are three hepatitis C treatments — Sovaldi and Harvoni, which are sold by Gilead Sciences, and the Viekira Pak medication sold by AbbVie. These medicines helped spark widening concerns last year over affordability.
Complete article on The Wall Street Journal: http://on.wsj.com/1zL7Cvf
IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies
November 21st 2023A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Read More
Overcoming Challenges to Value-Based Care Implementation: Grant Andres
November 10th 2023In an interview with The American Journal of Managed Care®, Grant Andres, BSc, DC, BSN, MSN-RN, senior director of clinical operations at Arizona Oncology, discussed the nuances of successfully implementing value-based care initiatives across a large organization.
Read More
